Everest Organics Ltd.

N.A.
AS ON 10 16 AM | 10 201
BSE
171.00-3.00-1.72%
Today's Trend
Low
80.00
High
245.00
Volume
2555.00
Open
178.50
Prev Close
174.00
x
Add to Portfolio
Add to Watchlist

Technical Chart

  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
Bid
Offer

Mkt Cap (₹ Cr.)

136.80

Face Value (₹)

10.00
10.00
P/E (x)
14.32
EPS-TTM(₹)
11.94
11.94
P/B (x)
5.27
BV/Sh(x)
32.47
32.47
Div. Yield(%)
0.58
52Wk L/H
NaN
NaN
80.00
245.00


News & Recos

  • Disclosure Of Related Party Transactions
    Pursuant to the Regulation 23(9) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, please find enclosed herewith the applicable disclosure on Related Party Transactions for the half year ended September 30, 2019 in the requisite format.
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Srihari Raju Srikakarlapudi
  • Announcement under Regulation 30 (LODR)-Newspaper Publication
    We hereby inform you that the Company has published the Un-Audited Financial Results of the Company for the second quarter and half year ended 30th September, 2019 approved by the Board of Directors at their Meeting held on Monday the 11th November, 2019, in Business Standard (English Newspaper) and Nava Telangana (Telugu Newspaper) on 13.11.2019, in accordance with Regulation 47 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015.
  • Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Everest Organics Limited reports strong H1 Revenue growth 27%; PAT growth of 66% on Half yearly basis Everest Organics Limited announced its financial results for the second quarter and half year ended September 30, 2019 (Q2 of FY 2019-20) Income from Operations ("Revenue") was INR 81.23 Crores as compared to INR 63.59 Crores in the previous year. Profit after Taxes and Minority Interest ("PAT") was INR 5.13 Cr. as compared to INR 3.08 Cr. in the previous year registering a significant growth of 66.56% in PAT.
  • Announcement under Regulation 30 (LODR)-Newspaper Publication
    Everest Organics Limited reports strong H1 Revenue growth 27%; PAT growth of 66% on Half yearly basis Everest Organics Limited announced its financial results for the second quarter and half year ended September 30, 2019 (Q2 of FY 2019-20) Income from Operations ("Revenue") was INR 81.23 Crores as compared to INR 63.59 Crores in the previous year. Profit after Taxes and Minority Interest ("PAT") was INR 5.13 Cr. as compared to INR 3.08 Cr. in the previous year registering a significant growth of 66.56% in PAT.
  • Un-Audited Financial Result For The Second Quarter And Half Year Ended September 30, 2019.
    Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform you that the Board of Directors of the company in its meeting held today i.e. 11.11.2019 have considered and approved the Un-audited Financial Results for the second quarter and half year ended September 30, 2019 along with Statement of Assets & Liabilities, Cash Flow Statement and Limited Review Report thereon.
  • Outcome of Board Meeting
    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, November 11, 2019, has inter-alia, considered and approved the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2019, as recommended by the Audit Committee and approved by the Board of Directors of the Company together with the statement of financial results, Statement of Assets & Liabilities, Cash Flow Statement and Limited Review Report of the Statutory Auditors thereon pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.
  • Announcement under Regulation 30 (LODR)-Newspaper Publication
    We hereby inform you that the Company has published the Notice of its Board Meeting to be held on Monday, the 11th day of November, 2019, in Business Standard(English Newspaper) and in Nava Telangana (Telugu Newspaper), in accordance with Regulation 47 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015.
  • Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Results Of The Company For The Second Quarter Ended September 30,2019
    EVEREST ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2019 ,inter alia, to consider and approve the Un-Audited Financial Results of the Company for the second quarter ended September 30, 2019 to be held on Monday, November 11, 2019 at 11:30 a.m., at the Corporate Office of the Company at Hyderabad. Further, kindly note that pursuant to the Company Code of Conduct to Regulate, Monitor and Report share trading by Designated Persons, the trading window closure for dealing in the securities of the Company commenced on October 01, 2019 and shall reopen after 48 hours of the declaration of financial results of the Company i.e. on November 13, 2019 (both days inclusive). Kindly take the above information on record.
  • Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
    This is with reference to the captioned subject, we hereby inform you that the Company has received information from the shareholders regarding loss of share certificates and after complying with the required formalities the company has issued the duplicate share certificates as enclosed;
MORE FROM NEWS & RECOS

Earnings
(Figures in Rs. Cr.)

Sales

Other Operating
Income

Operating Profit

Other Income

EBITDA

Interest

Depreciation

Tax

Net Profit

EPS (₹)

Sep 2019
% Chg (Quarterly)
% Chg (Yearly)
Peer Range
Trend
39.99
-3.04
9.41
0.00
3446.00
0.00
0.00
0.00
0.00
158.28
4.33
-29.06
-1.49
-62.92
1457.90
0.20
-7.20
966.49
0.00
408.00
4.54
-28.30
2.70
-60.66
1237.50
0.75
-13.19
-15.51
0.00
114.47
0.78
2.89
11.77
0.00
204.10
1.12
-23.64
96.56
-343.90
182.52
1.89
-41.73
-16.64
-71.64
1365.10
2.36
-41.73
-16.61
-9.50
82.24

Stock Performance

Period:
Company
LTP
%Change
Trend

Financial Comparison with peers

Management Efficiency

Return On Equity (%)

Return On Assets (%)

Return On Capital Employed (%)

Fixed Assets Turnover (x)

Profitability & Growth

Gross Profit Margin (%)

Operating Profit Margin (%)

Net Profit Margin (%)

Financial Strength
Liquidity

Quick Ratio (x)

Current Ratio (x)

Cash Ratio (x)

Solvency

Debt Equity Ratio (x)

Coverage Ratios

Cash Flows to Long Term Debt (x)

Peer
Average
Peer Range
Trend
28.90
-5.36
-815.24
82.35
7.00
-2.17
-638.80
56.76
29.70
6.08
-170.35
106.41
3.78
1.32
-23.65
24.31
9.62
-17.14
-2359.83
37.79
11.44
-11.41
-2359.83
50.28
4.81
-25.98
-2360.12
53.08
0.80
7.18
0.11
416.33
1.10
7.83
0.13
416.33
0.03
1.11
0.00
51.05
0.19
0.41
0.00
7.18
1.82
6.52
0.00
425.55

Share Holding

  • Categories
    No. Of Shares
    %
  • Promoters
    5,706,502
    71.33
  • NoOfShares
    8,000,000
    100.00
  • GeneralPublic
    1,311,486
    16.39
  • Others
    810,670
    10.13
  • ForeignPromoter
    169,128
    2.11
  • FinancialInstitutions
    2,214
    0.03

About

Everest Organics Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 136.80 Crore) operating in Pharmaceuticals sector.

Everest Organics Ltd. key Products/Revenue Segments include Omeprazole which contributed Rs 31.58 Crore to Sales Value (28.15 % of Total Sales), Esomeprazole which contributed Rs 20.67 Crore to Sales Value (18.42 % of Total Sales), Pantaprazole which contributed Rs 17.08 Crore to Sales Value (15.22 % of Total Sales), Chlorinated Compounds which contributed Rs 16.13 Crore to Sales Value (14.37 % of Total Sales), Others which contributed Rs 16.04 Crore to Sales Value (14.29 % of Total Sales), Benzimidazole which contributed Rs 4.70 Crore to Sales Value (4.18 % of Total Sales), Sulphide which contributed Rs 2.55 Crore to Sales Value (2.26 % of Total Sales), Tetralone which contributed Rs 2.07 Crore to Sales Value (1.84 % of Total Sales), Ammonium Sulphate which contributed Rs 1.37 Crore to Sales Value (1.22 % of Total Sales)for the year ending 31-Mar-2018.

For the quarter ended 30-09-2019, the company has reported a Standalone sales of Rs 39.99 Crore, down -3.04 % from last quarter Sales of Rs 41.24 Crore and up 9.41 % from last year same quarter Sales of Rs 36.55 Crore Company has reported net profit after tax of Rs 1.89 Crore in latest quarter.

The company’s top management includes Dr.S K Sirisha, Dr.S K Srihari Raju, Mr.A Parvatisem, Mr.K Ramakrishnam Raju, Mr.Raju S Kakarlapudi, Mr.S K Hari Krishna, Mr.Sreeramakrishna Grandhi, Mr.V Swaminathan. Company has Suryam & Co. as its auditoRs As on 30-09-2019, the company has a total of 8,000,000 shares outstanding.

Loading data...
Text Size:AAA

*

Markets Data
GetET MarketsAPP